Medicenna Therapeutics Corp (MDNAF) Price & Analysis

Compare

222 Followers

MDNAF Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.57 - $1.94

Previous CloseN/A

Volume34.40K

Average Volume (3M)48.16K

Market Cap

C$53.75M

Enterprise Value$49.85M

Total Cash (Recent Filing)C$24.84M

Total Debt (Recent Filing)C$168.00K

Price to Earnings (P/E)―

Beta1.40

Next Earnings

Nov 14, 2025

EPS Estimate

-0.05

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.04

Shares Outstanding68,726,980

10 Day Avg. Volume92,845

30 Day Avg. Volume48,157

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

C$2.51

Price Target Upside230.19% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe first complete response was reported in the combination of MDNA11 and pembrolizumab in a patient with advanced anal squamous cell carcinoma.

Drug DevelopmentManagement hopes to validate the positive signal in cancers, with potential to pursue an accelerated approval path.

Bears Say

Regulatory ChallengesThe company continues to enroll all-comers in the combo dose escalation as they seek out responses in patients with tumors not generally expected to respond to pembrolizumab.

Medicenna Therapeutics Corp News

Medicenna Therapeutics Reports Strong Clinical Progress and Financial Stability in Q1 Fiscal 2026

Medicenna Therapeutics Corp ( ($TSE:MDNA) ) just unveiled an update. Medicenna Therapeutics Corp reported its first-quarter fiscal 2026...

15d ago

Medicenna Expands IP Portfolio with Five New Patents for Superkines

An update from Medicenna Therapeutics Corp ( ($TSE:MDNA) ) is now available. Medicenna Therapeutics Corp has announced the...

15d ago

Medicenna Reports Promising Fiscal 2025 Results and Advances in Immunotherapy Programs

Medicenna Therapeutics Corp ( ($TSE:MDNA) ) has provided an update. Medicenna Therapeutics Corp reported its fiscal year 2025...

2M ago

MDNA Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Medicenna Therapeutics (MDNA) is scheduled to report 4th quarter earnings on 06/25/2025. Regarding Q4 estimates, Wall Street analysts...

2M ago

Medicenna Unveils Promising Preclinical Results for Novel Cancer Therapy

The latest announcement is out from Medicenna Therapeutics Corp ( ($TSE:MDNA) ). Medicenna Therapeutics Corp has presented promising...

4M ago

Promising Clinical Trial Results Boost Buy Rating for Medicenna Therapeutics Corp

In a report released today, David Martin PhD from Bloom Burton maintained a Buy rating on Medicenna Therapeutics...

4M ago

Medicenna’s MDNA11 Shows Promising Results in Cancer Trial

Medicenna Therapeutics Corp ( ($TSE:MDNA) ) has issued an update. Medicenna Therapeutics Corp has presented promising results from...

4M ago

Medicenna to Present at 2025 Healthcare Investor Conference

Medicenna Therapeutics Corp ( ($TSE:MDNA) ) has shared an update. Medicenna Therapeutics Corp announced that its President and...

4M ago

Medicenna to Present at Healthcare Innovation Conference

Medicenna Therapeutics Corp ( ($TSE:MDNA) ) has shared an announcement. Medicenna Therapeutics Corp announced that its President and...

5M ago

Medicenna to Present Key Updates at AACR 2025

The latest announcement is out from Medicenna Therapeutics Corp ( ($TSE:MDNA) ). Medicenna Therapeutics Corp announced that it...

5M ago

Medicenna Therapeutics CFO Jeff Caravella, CBO Brent Meadows depart

The Company announced the departure of Jeff Caravella as Chief Financial Officer, and Brent Meadows as Chief Business...

2y ago

MDNA

Medicenna Therapeutics reduces size of management team, U.S. presence

In connection with the Nasdaq delisting and in effort to further preserve capital, the Board decided to reduce...

2y ago

MDNA

Medicenna Therapeutics to seek listing of common shares on OTC Markets

After careful consideration, the Board of Directors of Medicenna determined that it is in the overall best interests...

2y ago

MDNA

Medicenna Therapeutics announces Nasdaq delisting

Medicenna Therapeutics announced that the Company received a Staff Delisting Determination from the Listing Qualifications Department of the...

2y ago

MDNA

MDNAF FAQ

What was Medicenna Therapeutics Corp’s price range in the past 12 months?

Medicenna Therapeutics Corp lowest stock price was $0.57 and its highest was $1.94 in the past 12 months.

What is Medicenna Therapeutics Corp’s market cap?

Medicenna Therapeutics Corp’s market cap is C$53.75M.

When is Medicenna Therapeutics Corp’s upcoming earnings report date?

Medicenna Therapeutics Corp’s upcoming earnings report date is Nov 14, 2025 which is in 91 days.

How were Medicenna Therapeutics Corp’s earnings last quarter?

Medicenna Therapeutics Corp released its earnings results on Aug 01, 2025. The company reported -$0.044 earnings per share for the quarter, the consensus estimate of -$0.044 by $0.

Is Medicenna Therapeutics Corp overvalued?

According to Wall Street analysts Medicenna Therapeutics Corp’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Medicenna Therapeutics Corp pay dividends?

Medicenna Therapeutics Corp does not currently pay dividends.

What is Medicenna Therapeutics Corp’s EPS estimate?

Medicenna Therapeutics Corp’s EPS estimate is -0.05.

How many shares outstanding does Medicenna Therapeutics Corp have?

Medicenna Therapeutics Corp has 68,726,980 shares outstanding.

What happened to Medicenna Therapeutics Corp’s price movement after its last earnings report?

Medicenna Therapeutics Corp reported an EPS of -$0.044 in its last earnings report, expectations of -$0.044. Following the earnings report the stock price went down -2.439%.

Which hedge fund is a major shareholder of Medicenna Therapeutics Corp?

Currently, no hedge funds are holding shares in MDNAF

Medicenna Therapeutics Corp Stock Smart Score

Neutral

Fundamentals

Return on Equity

-69.80%

Trailing 12-Months

Asset Growth

-40.12%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Medicenna Therapeutics Corp

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.

Medicenna Therapeutics Corp (MDNAF) Earnings & Revenues

Historic Earnings Reports

MDNAF Stock 12 Month Forecast

Average Price Target

$2.51

▲(230.19% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","1":"$1","2":"$2","3":"$3","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2.511230704976,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2.51</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.5094748,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.51</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.511230704976,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.51</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0,1,2,3],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.867,0.9934792849981539,1.1199585699963077,1.2464378549944617,1.3729171399926154,1.4993964249907692,1.6258757099889232,1.7523549949870771,1.878834279985231,2.0053135649833846,2.1317928499815384,2.2582721349796926,2.3847514199778463,{"y":2.511230704976,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.867,0.9933442153846154,1.1196884307692307,1.246032646153846,1.3723768615384615,1.498721076923077,1.6250652923076923,1.7514095076923075,1.877753723076923,2.0040979384615385,2.130442153846154,2.256786369230769,2.3831305846153845,{"y":2.5094748,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.867,0.9934792849981539,1.1199585699963077,1.2464378549944617,1.3729171399926154,1.4993964249907692,1.6258757099889232,1.7523549949870771,1.878834279985231,2.0053135649833846,2.1317928499815384,2.2582721349796926,2.3847514199778463,{"y":2.511230704976,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.459,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.28,"date":1696118400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.157,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.32,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.33,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.67,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.81,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.13,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.145,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.88,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.711,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.68,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.867,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >